NRX NurExone Biologic Inc.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.…
Industry Peers
BiotechnologyKey Statistics
About NurExone Biologic (CVE: NRX)
›
NurExone Biologic (CVE: NRX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.4900 CAD on 19 November 2026, down 31.0% over 52 weeks. Its 52-week range is 0.4350 CAD to 0.7600 CAD: the price is 35.5% below the high and 12.6% above the low.
Its market capitalisation is 45.10M CAD.
NurExone Biologic reports return on equity of -231.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 954.00K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 November 2026.